×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ANIX – anixa biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ANIX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/22
08:15 am
anix
Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
High
Report
Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
11/19
08:20 am
anix
Anixa Biosciences, Inc. (NASDAQ: ANIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Low
Report
Anixa Biosciences, Inc. (NASDAQ: ANIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
11/18
08:20 am
anix
Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial
Low
Report
Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial
11/14
05:18 pm
anix
Breast cancer vaccine update from Cleveland Clinic: ‘A new era' [FOX News]
Medium
Report
Breast cancer vaccine update from Cleveland Clinic: ‘A new era' [FOX News]
11/8
01:23 pm
anix
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting [Yahoo! Finance]
Low
Report
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting [Yahoo! Finance]
11/8
01:17 pm
anix
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Medium
Report
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/6
08:30 am
anix
Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Low
Report
Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
10/31
08:15 am
anix
Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024
Medium
Report
Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
11/8
01:32 pm
anix
Form 8-K Anixa Biosciences Inc For: Nov 08
Low
Report
Form 8-K Anixa Biosciences Inc For: Nov 08
10/23
11:28 am
anix
Form 4 Anixa Biosciences Inc For: Oct 22 Filed by: Titterton Lewis H jr
Medium
Report
Form 4 Anixa Biosciences Inc For: Oct 22 Filed by: Titterton Lewis H jr
9/6
05:01 pm
anix
Form 10-Q Anixa Biosciences Inc For: Jul 31
Low
Report
Form 10-Q Anixa Biosciences Inc For: Jul 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/17
Anixa Biosciences Announces a Strategic Alliance and Licensing Agreement with Cleveland Clinic for an Innovative Breast Cancer Vaccine Technology
13.1%
12/30 ITUS Corporation (NYSE: ANIX) had its price target lowered by analysts at B. Riley from $11.25 to $8.00. They now have a "buy" rating on the stock. 11.8%
1/14 Form 4 Anixa Biosciences Inc For: Jan 14 Filed by: KUMAR AMIT 10.4%
11/26 Anixa Biosciences Announces Genesis Research to Join Cchek™ Prostate Cancer Study 7.3%
1/16 Form 4 Anixa Biosciences Inc For: Jan 15 Filed by: Titterton Lewis H jr 6.9%
10/15 Anixa Biosciences Appoints Dr. Thomas Schlumpberger as Executive Vice President of Diagnostics to Head Liquid Biopsy Development and Commercialization Efforts 5.7%
12/23 Anixa Biosciences to Present at Biotech Showcase 2020 5.5%
4/27 ITUS Corporation (NYSE: ANIX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 4.8%
1/21 Form 4 Anixa Biosciences Inc For: Jan 17 Filed by: Baskies Arnold M 4.8%
8/21 Form 8-K Anixa Biosciences Inc For: Aug 21 4.6%
12/30 ITUS Corporation (NYSE: ANIX) had its price target lowered by analysts at B. Riley from $11.25 to $8.00. They now have a "buy" rating on the stock. 11.8%
1/14 Form 4 Anixa Biosciences Inc For: Jan 14 Filed by: KUMAR AMIT 10.4%
11/26 Anixa Biosciences Announces Genesis Research to Join Cchek™ Prostate Cancer Study 7.3%
1/16 Form 4 Anixa Biosciences Inc For: Jan 15 Filed by: Titterton Lewis H jr 6.9%
10/15 Anixa Biosciences Appoints Dr. Thomas Schlumpberger as Executive Vice President of Diagnostics to Head Liquid Biopsy Development and Commercialization Efforts 5.7%
12/23 Anixa Biosciences to Present at Biotech Showcase 2020 5.5%
4/27 ITUS Corporation (NYSE: ANIX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 4.8%
1/21 Form 4 Anixa Biosciences Inc For: Jan 17 Filed by: Baskies Arnold M 4.8%
8/21 Form 8-K Anixa Biosciences Inc For: Aug 21 4.6%
TOP News Decliners
3/9
Q1/2020 1/31/2020 EPS -0.130 ZacksConsensus -0.130 ActVsEst 0.000 - In-Line
-18.5%
12/13 Anixa Biosciences Provides Update on CAR-T Program -15.1%
4/20 Anixa Bio up 30% premarket on plan to develop COVID-19 drugs [Seeking Alpha] -12.6%
1/1 ITUS Corporation (NYSE: ANIX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.50 price target on the stock. -8.5%
3/23 ITUS Corporation (NYSE: ANIX) is now covered by analysts at Aegis. They set a "buy" rating and a $8.50 price target on the stock. -6.1%
3/24 ITUS Corporation (NYSE: ANIX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.0%
7/18 Form 8-K Anixa Biosciences Inc For: Jul 12 -4.4%
6/11 Form S-3 Anixa Biosciences Inc -3.6%
1/10 Form 10-K/A Anixa Biosciences Inc For: Oct 31 -3.5%
4/20 ITUS Corporation (NYSE: ANIX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. -3.4%
12/13 Anixa Biosciences Provides Update on CAR-T Program -15.1%
4/20 Anixa Bio up 30% premarket on plan to develop COVID-19 drugs [Seeking Alpha] -12.6%
1/1 ITUS Corporation (NYSE: ANIX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.50 price target on the stock. -8.5%
3/23 ITUS Corporation (NYSE: ANIX) is now covered by analysts at Aegis. They set a "buy" rating and a $8.50 price target on the stock. -6.1%
3/24 ITUS Corporation (NYSE: ANIX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.0%
7/18 Form 8-K Anixa Biosciences Inc For: Jul 12 -4.4%
6/11 Form S-3 Anixa Biosciences Inc -3.6%
1/10 Form 10-K/A Anixa Biosciences Inc For: Oct 31 -3.5%
4/20 ITUS Corporation (NYSE: ANIX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. -3.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: